Home
About
Overview
Management Team
Board of Directors
Partners
Product Pipeline
Overview
Iomab-B
Actimab-A
Iomab-ACT for Gene & Cell Therapy Conditioning
Clinical Trial Information
Publications
AWE Technology
Actinium-225 Technology
Investors
Investor Relations
Overview
News / Events
Press Releases
IR Calendar
Video Gallery
Email Alerts
Company Info
Profile
Presentations & Webinars
Contacts
Analyst Coverage
FAQ
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Governance
Board of Directors
Board Committees
Governance Documents
Careers
Contact
Home
Investors
SEC Filings
All SEC Filings
Investors
Overview
News / Events
Company Information
Stock Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Corporate Governance
Email Alerts
Contacts
Twitter
RSS News Feed
All SEC Filings
Filter Filings:
View All
10-K
10-K/A
10-Q
10-Q/A
10KSB
10KSB/A
10QSB
10SB12G
3
3/A
4
424B3
424B5
8-A12B
8-K
8-K/A
ARS
CERTNYS
CORRESP
D
D/A
DEF 14A
DEF 14C
DEFA14A
EFFECT
NT 10-K
NT 10-Q
PRE 14A
PRE 14C
PRER14A
RW
S-1
S-1/A
S-3
S-3/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC 14F1
UPLOAD
Date
Form
Description
Docs
XBRL
Pages
11/04/24
SC 13G/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
2
08/05/24
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
40
08/05/24
8-K
Current report filing
Related Documents
EX-99.1
4
04/26/24
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
50
03/29/24
S-8
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Related Documents
EX-5.1
EX-23.1
EX-FILING FEES
6
03/29/24
10-K
Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
EX-97.1
76
02/09/24
SC 13G/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
9
02/05/24
EFFECT
Notice of Effectiveness
1
02/02/24
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
02/02/24
S-3/A
Registration statement for specified transactions by certain issuers
Related Documents
EX-23.1
EX-FILING FEES
27
<< Previous
1
2
3
4
5
6
7
8
9
10
...48
Next >>